SE0203137D0 - Drug target in cancer therapy - Google Patents
Drug target in cancer therapyInfo
- Publication number
- SE0203137D0 SE0203137D0 SE0203137A SE0203137A SE0203137D0 SE 0203137 D0 SE0203137 D0 SE 0203137D0 SE 0203137 A SE0203137 A SE 0203137A SE 0203137 A SE0203137 A SE 0203137A SE 0203137 D0 SE0203137 D0 SE 0203137D0
- Authority
- SE
- Sweden
- Prior art keywords
- cancer therapy
- drug target
- relates
- cyp2w1
- therapeutic agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0203137A SE0203137D0 (sv) | 2002-10-24 | 2002-10-24 | Drug target in cancer therapy |
| US10/532,014 US20060166912A1 (en) | 2002-10-24 | 2003-10-24 | Use of cytochrome p450 enzyme cyp2w1 as a drug target for cancer theraphy |
| AT03754349T ATE435027T1 (de) | 2002-10-24 | 2003-10-24 | Einsatz des cytochrom p450-enzyms cyp2wi als zielmolekül für wirkstoffe bei der krebstherapie |
| AU2003272180A AU2003272180A1 (en) | 2002-10-24 | 2003-10-24 | The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy |
| CNA2003801055321A CN1753689A (zh) | 2002-10-24 | 2003-10-24 | 细胞色素p450酶cyp2w1作为药物目标用于癌症治疗的用途 |
| PCT/SE2003/001652 WO2004037282A1 (en) | 2002-10-24 | 2003-10-24 | The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy |
| EP03754349A EP1565208B1 (en) | 2002-10-24 | 2003-10-24 | The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy |
| DE60328218T DE60328218D1 (de) | 2002-10-24 | 2003-10-24 | Einsatz des cytochrom p450-enzyms cyp2wi als zielmolekül für wirkstoffe bei der krebstherapie |
| US12/046,136 US20080242637A1 (en) | 2002-10-24 | 2008-03-11 | Use of Cytochrome P450 Enzyme CYP2WI as a Drug Target for Cancer Therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0203137A SE0203137D0 (sv) | 2002-10-24 | 2002-10-24 | Drug target in cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0203137D0 true SE0203137D0 (sv) | 2002-10-24 |
Family
ID=20289352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0203137A SE0203137D0 (sv) | 2002-10-24 | 2002-10-24 | Drug target in cancer therapy |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20060166912A1 (xx) |
| EP (1) | EP1565208B1 (xx) |
| CN (1) | CN1753689A (xx) |
| AT (1) | ATE435027T1 (xx) |
| AU (1) | AU2003272180A1 (xx) |
| DE (1) | DE60328218D1 (xx) |
| SE (1) | SE0203137D0 (xx) |
| WO (1) | WO2004037282A1 (xx) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1907420T3 (pl) * | 2005-07-21 | 2017-09-29 | Modiquest B.V. | Pleksyna D1 jako obiekt docelowy do diagnozowania i leczenia guza |
| KR20240161207A (ko) | 2015-05-06 | 2024-11-12 | 이매틱스 바이오테크놀로지스 게엠베하 | 결장직장 암종(crc) 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드와 이의 골격의 조합 |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003201D0 (en) * | 2000-02-11 | 2000-04-05 | Pharmacia & Upjohn Spa | Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
-
2002
- 2002-10-24 SE SE0203137A patent/SE0203137D0/xx unknown
-
2003
- 2003-10-24 WO PCT/SE2003/001652 patent/WO2004037282A1/en not_active Ceased
- 2003-10-24 EP EP03754349A patent/EP1565208B1/en not_active Expired - Lifetime
- 2003-10-24 AT AT03754349T patent/ATE435027T1/de not_active IP Right Cessation
- 2003-10-24 AU AU2003272180A patent/AU2003272180A1/en not_active Abandoned
- 2003-10-24 CN CNA2003801055321A patent/CN1753689A/zh active Pending
- 2003-10-24 DE DE60328218T patent/DE60328218D1/de not_active Expired - Fee Related
- 2003-10-24 US US10/532,014 patent/US20060166912A1/en not_active Abandoned
-
2008
- 2008-03-11 US US12/046,136 patent/US20080242637A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080242637A1 (en) | 2008-10-02 |
| CN1753689A (zh) | 2006-03-29 |
| AU2003272180A1 (en) | 2004-05-13 |
| EP1565208A1 (en) | 2005-08-24 |
| WO2004037282A1 (en) | 2004-05-06 |
| EP1565208B1 (en) | 2009-07-01 |
| ATE435027T1 (de) | 2009-07-15 |
| DE60328218D1 (de) | 2009-08-13 |
| US20060166912A1 (en) | 2006-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1742644T3 (pl) | Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny | |
| EP1844077A4 (en) | DR5 ANTIBODIES AND THEIR USE | |
| LUC00011I2 (xx) | ||
| MX2007003907A (es) | Agentes terapeuticos con toxicidad reducida. | |
| EP2061456A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING P450 CYTOCHROME | |
| LU92203I9 (xx) | ||
| MY144632A (en) | Cytotoxic agents comprising new taxanes | |
| WO2004094614A3 (en) | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics | |
| WO2006113483A3 (en) | Methods and compositions for treating or preventing cancer | |
| TW200642682A (en) | A combination of medical drugs to augment the anti-cancer effect of chemotherapy | |
| SE0203137D0 (sv) | Drug target in cancer therapy | |
| WO2006050498A3 (en) | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics | |
| WO2003026696A1 (fr) | Procede permettant de maitriser la proliferation de cellules cancereuses et la mort cellulaire | |
| ATE490981T1 (de) | Criptospezifische antikörper |